Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARQIBO KIT vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after two or more anti-leukemia therapies
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily hepatic metabolism via CYP3A4; also undergoes biliary excretion.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 75% bound to plasma proteins, primarily to albumin and beta-globulins.
47% bound to plasma proteins (primarily albumin)
Volume of distribution (Vd) is 4.0-7.9 L/kg (mean 5.6 L/kg), indicating extensive tissue binding and distribution into tissues, consistent with its lipophilic nature.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Not applicable; Marqibo is administered intravenously only. Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux.
IV: 100% (only IV route); oral: not approved
No specific dose adjustment guidelines. Use caution in patients with creatinine clearance <50 m L/min due to potential for increased exposure.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh B), reduce dose to 1.8 mg/m2 every 7 days. Mild impairment (Child-Pugh A): no adjustment necessary.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in patients <18 years. Data limited to case reports; no standard dosing guidelines available.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment based on age alone. Monitor closely for increased toxicity (e.g., neurotoxicity, myelosuppression) due to potential for decreased organ function and comorbidities.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
MARQIBO is for intravenous use only. Fatal if given intrathecally. Use only with a medical provider experienced in the administration of chemotherapeutic agents. Contains vincristine sulfate, a vesicant. Ensure proper administration technique.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Extensive extravasation precautions required; neurotoxicity (peripheral neuropathy, autonomic neuropathy); hematologic toxicity (myelosuppression); gastrointestinal toxicity (constipation, ileus); hepatic impairment; monitor serum uric acid levels; embryo-fetal toxicity.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to vincristine or any component of the formulation; patients with demyelinating conditions (e.g., Charcot-Marie-Tooth syndrome); intrathecal administration.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and alter drug levels. Avoid St. John's wort as it may induce CYP3A4 and reduce efficacy. No specific food restrictions other than these. Maintain adequate hydration to prevent tumor lysis syndrome.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
No data on presence in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment and for at least 2 weeks after last dose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No established dose adjustments for pregnancy due to lack of studies. Pharmacokinetic changes (increased volume of distribution, decreased clearance) may necessitate dose modifications based on tolerability and response. Use lowest effective dose.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
MARQIBO KIT (vincristine sulfate liposome injection) is indicated for adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory acute lymphoblastic leukemia (ALL). It is a liposomal formulation of vincristine that prolongs drug exposure and enhances tumor delivery. Administer intravenously over 1 hour at a dose of 2.25 mg/m² without a maximum dose cap, unlike standard vincristine. Do not substitute for other vincristine formulations. Monitor for neurotoxicity, including peripheral neuropathy, autonomic neuropathy (constipation, ileus), and cranial nerve palsies. Premedicate with corticosteroids and antiemetics. Avoid concomitant use of strong CYP3A4 inducers or inhibitors due to altered metabolism. Neurotoxicity is dose-limiting and may require dose reduction or discontinuation. Tumor lysis syndrome may occur; ensure adequate hydration and allopurinol. Pregnancy category D; verify pregnancy status. Extravasation management is similar to other vinca alkaloids (apply heat, hyaluronidase).
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
This medication is a form of chemotherapy given intravenously for a type of leukemia.,It may cause nerve damage; report numbness, tingling, pain, weakness, or constipation immediately.,Do not receive any live vaccines during treatment and for 6 months after.,Use effective contraception during treatment and for at least 1 month after the last dose.,Avoid grapefruit juice and St. John's wort while on this medication.,Drink plenty of fluids to prevent tumor lysis syndrome.,Report any signs of infection (fever, chills) or bleeding (easy bruising, black stools).
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARQIBO KIT vs CLOFARABINE, answered by our medical review team.
MARQIBO KIT is a Antineoplastic Agent that works by Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARQIBO KIT and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARQIBO KIT is: 2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARQIBO KIT and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARQIBO KIT is classified as Category C. Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.